Overview

A Study to Evaluate the Safety and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis

Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for fibrosis and oncology. This study is a four-part trial consisting of Parts A, B C and D. Parts A and B are presented in this record, while Parts C and D are currently not recruiting. The primary objective in Parts A and B of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of single and multiple doses of LASN01 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Lassen Therapeutics 1, Inc.